Contrast-enhanced ultrasound: State of the art in North America
On October 24, 2017, in Chicago, the Society of Radiologists in Ultrasound convened a panel of specialists in contrast-enhanced ultrasound (CEUS) to arrive at a white paper regarding the use of CEUS in noncardiac applications in North America. Recommendations are based on analysis of the current literature and common practice strategies. They represent a reasonable approach to introduce the advantages of this safe and noninvasive technique for the benefit of our patients. Characterization of liver nodules with CEUS, as the approval indication worldwide, is the major focus of this endeavor. In addition, many off label uses are reviewed and literature supporting these indications provided.Key Points(1) Contrast-enhanced ultrasound (CEUS) allows cross-sectional imaging of the liver, kidneys and multiple other solid and hollow viscera, providing excellent characterization of identified focal mass lesions.(2) Performed with the injection of a microbubble contrast agent, CEUS provides a safe and readily available imaging technique which requires no ionizing radiation, making it appropriate for use in all ages, in those with renal insufficiency and when a portable examination is needed.(3) The CEUS can be considered in abdominal imaging whenever blood flow information is of value to diagnosis.(4) Dynamic real-time acquisition and the use of a purely intravascular contrast agent are the 2 most essential technical aspects of CEUS imaging which distinguish it from both computed tomography and magnetic resonance scan.
Barr RG;Wilson SR;Lyshchik A;McCarville B;Darge K;Grant E;Robbin M;Wilmann JK;Chong WK;Fleischer A;Paltiel HJ
Ultrasound Quarterly
2020
2020-09-19
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1097/ruq.0000000000000515" target="_blank" rel="noreferrer noopener">10.1097/ruq.0000000000000515</a>
Contrast-enhanced ultrasound: State of the art in North America
safety; ultrasound contrast agents; AP = arterial phase; APHE = arterial phase hyperenhancement; CEUS = contrast-enhanced ultrasound; FLL = focal liver lesion; FNH = focal nodular hyperplasia; kidney masses; lesion characterization; liver masses; UCA = ultrasound contrast agent; ultrasound contrast
The Society of Radiologists in Ultrasound convened a panel of specialists in contrast-enhanced ultrasound (CEUS) to produce a white paper on noncardiac CEUS in North America. The panel met in Chicago, Illinois, on October 24 and 25, 2017. The recommendations are based on analysis of current literature and common practice strategies and are thought to represent a reasonable approach to introduce the advantages of this safe and noninvasive technique for the benefit of our patients. Characterization of liver nodules, and pediatric vascular and intravesicular applications comprise the approved indications for CEUS in the United States. They, along with the very successful off-label use of CEUS for the kidney, are included in this publication.Other off-label uses are presented with emphasis on their value and literature support in the online version.
Barr RG;Wilson SR;Lyshchik A;McCarville B;Darge K;Grant E;Robbin M;Wilmann JK;Chong WK;Fleischer A;Paltiel HJ
Ultrasound Quarterly
2020
2020-09
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1097/ruq.0000000000000514" target="_blank" rel="noreferrer noopener">10.1097/ruq.0000000000000514</a>